Analyzing Nano Drugs - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Analyzing Nano Drugs

Manufacturers, scientists, and regulators are examining methods for characterizing nanomaterials in drug formulation and production and the need for clear US and international standards in this area. Nano drugs are the subject of a Jan. 14-15, 2014 workshop on the the risks and opportunities of developing nanomaterial drug products, sponsored by the Product Quality Research Institute (PQRI), the US Pharmacopeial Convention, American Association of Pharmaceutical Scientists (AAPS), and FDA. The aim is to encourage more collaboration between academia, industry, and government on relevant research. Experts from FDA and other regulatory authorities will describe efforts to evaluate potential risks from use of nanomaterials in drug products and discuss analytical considerations, impact on stability, safety, and toxicology effects.

This program is timely because of growing interest in FDA moving beyond the examination of nanomaterials in sunscreens and other topicals to opportunities for improving the delivery of treatments for cancer and other serious conditions. The New York Academy of Sciences held a conference in November 2013 on the application of nanotechnology to nanomedicine, featuring experts from the National Characterization Laboratory of the National Cancer Institute discussing the development of new cancer therapies and product characterization. FDA’s 2013 nanotechnology regulatory science research plan outlines a range of activities that would improve staff training, expand laboratory facilities and promote collaborative research on nanotechnology. And the recently issued federal National Nanotechnology Initiative’s 2014 strategic plan describes FDA nano-related initiatives, pointing out the need for more scientific information to better detect and predict the potential impact of nano on drug safety, effectiveness and quality. An FDA blog posted October 24, 2013 describes the agency’s nano activities.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here